text:
Pakistan Swiftly Passes Resolution Calling for Public Hanging of Pedophiles
Human rights activists quickly condemned the passage of the resolution.
(TMU) — Pakistan's parliament passed a resolution Friday that calls for the public hanging of convicted child killers and rapists.
AFP reports that the resolution, which is non-binding, comes after a number of high-profile child sex-abuse cases have scandalized the South Asian nation in recent years, leading to major outbreaks of unrest and riots.
Parliamentary affairs minister Ali Muhammad Khan, who presented the resolution in the lower house of the legislature, said that child killers and rapists "should not only be given the death penalty by hanging, but they should be hanged publicly."
"The Quran commands us that a murderer should be hanged," the minister added.
While the resolution was swiftly passed by a majority of lawmakers, human rights minister Shireen Mazari has emphatically stated that it does not enjoy the backing of the government.
In a tweet, Mazari wrote:
"The resolution passed in [the National Assembly] today on public hangings was across party lines and not a govt-sponsored resolution but an individual act. Many of us oppose it – our [Ministry of Human Rights] strongly opposes this. Unfortunately I was in a mtg and wasn't able to go to NA."
Federal Minister for Science and Technology Fawad Chaudhry also condemned the passage of the resolution.
Chaudhry tweeted:
"Strongly condemn this resolution. This is just another grave act in line with brutal civilisation practices [sic]. Societies [should] act in a balanced way, [barbarity] is not an answer to crimes. This is another expression of extremism."
However, Pakistan has struggled to come to grips with rampant crimes of child sexual abuse.
A child rapist was hanged in October 2018 after his crime in Kasur, near Lahore, sparked days of nationwide protests and unrest.
Six-year-old victim Zainab Fatima Ameen was attacked by a 24-year-old man who later confessed to raping and murdering the young girl.
In 2015, authorities busted a huge paedophilia ring in Kasur. In the massive scandal, it was found that at least 280 children were being sexually abused by a gang who blackmailed parents with threats to publicly release the videos.
In March 2016, Pakistan criminalized sexual assault against minors, child pornography and trafficking. Only acts of rape and sodomy had previously been punishable by law.
Human rights NGO Amnesty International also condemned the recent passage of the bill by the lower house of parliament, with AI Deputy South Asia Director Omar Waraich noting that "public hangings are acts of unconscionable cruelty" with no place in a society that respects people's rights.
Continuing, the advocate said:
"Executions, whether public or private, do not deliver justice. They are acts of vengeance and there is no evidence that they serve as a uniquely effective deterrent."
A number of human rights groups have demanded that the country reinstate a moratorium on the death penalty. Capital punishment was reintroduced following the 2015 Army Public School massacre that claimed the lives of 151 people.
Sarah Belal, the executive director of anti-death penalty group Justice Project Pakistan, told AFP:
"There is no empirical evidence to show that public hangings are a deterrent to crime or in protecting the psycho-social well-being of children."


text:
Topic: Evan Rachel Wood
Latest Headlines Quotes Video
Evan Rachel Wood News
Movies // 5 months ago
'Kajillionaire': Evan Rachel Wood plays con artist in trailer for new film
"Kajillionaire," Miranda July's new film starring Evan Rachel Wood, Gina Rodriguez, Richard Jenkins and Debra Winger, will open in theaters in September.
'Into the Unknown': New series explores the making of 'Frozen 2'
Disney has released a new trailer for "Into the Unknown," which will chronicle the making of "Frozen 2."
FX renews 'What We Do In the Shadows' for Season 3
FX announced Friday it renewed the comedy "What We Do In the Shadows" for a third season.
What to binge next: 10 sci-fi shows to escape into the future
Here are 10 sci-fi shows to help you escape into a possible future that's not quite as dark as the present.
Evan Rachel Wood on 'Westworld': 'Certain things are final'
Evan Rachel Wood appeared on "The Tonight Show" and discussed the Season 3 finale of "Westworld."
HBO orders Season 4 of 'Westworld'
HBO said Wednesday it has ordered a fourth season of its sci-fi drama "Westworld."
'Westworld' Season 3 to premiere March 15
HBO has announced that Season 3 of "Westworld" will premiere on March 15 at 9 p.m. EDT.
Movies // 1 year ago
Josh Gad 'wept' at 'Frozen 2': 'Stunning and surprising'
Josh Gad, who voices Olaf in the "Frozen" movies, reacted after seeing "Frozen 2" for the first time.
'Frozen 2': Elsa, Anna find enchanted forest in new trailer
Elsa (Idina Menzel) and Anna (Kristen Bell) discover a mysterious magical forest in a new preview of Disney's "Frozen" sequel.
'Frozen 2' adds Evan Rachel Wood, Sterling K. Brown to voice cast
"Westworld" star Evan Rachel Wood and "This is Us" actor Sterling K. Brown have joined the voice cast of "Frozen 2."
Manson owns the house he lives in. My brother has never stayed there and the person that said such horrible things about Manson being 'controlling' and 'emotionally abusive' is certainly no source 'close' to me
Wood downplays Manson break-up rumors Nov 08, 2008
She has been trying to look like Dita, wearing sleek black dresses and hanging out everywhere he's been
Wood may have caused Manson divorce Jan 10, 2007
I was always into very androgynous things. Guys, girls ... . I'm into androgyny in general
People in the news Apr 19, 2011
Evan Rachel Wood says she's bisexual Apr 18, 2011
"The Ides of March" premiere in Beverly Hills
Evan Rachel Wood (born September 7, 1987) is an American actress and singer. She began her acting career in the late 1990s, appearing in several television series, including American Gothic and Once and Again. She made her debut as a leading film actress in Little Secrets (2002) and became well known after her transition to a more adult-oriented Golden Globe-nominated role in the teen drama film Thirteen (2003).
Wood continued acting mostly in independent films, including Pretty Persuasion (2005), Down in the Valley (2006), Running with Scissors (2006), and in the big studio production Across the Universe (2007). Wood's acting has drawn critical praise, and she has been described by The Guardian newspaper as being "wise beyond her years" and as "one of the best actresses of her generation." Wood was in a relationship with singer Marilyn Manson, to whom she was engaged until August 2010.
Evan Rachel Wood was born in Raleigh, North Carolina. Her father, Ira David Wood III, is a locally prominent actor, singer, theater director, and playwright who is the Executive Director of a local regional theatre company called Theatre in the Park. Her mother, Sara Lynn Moore (born March 6, 1958), is an actress, director and acting coach. Wood's brother, Ira David Wood IV, is also an actor; she has another brother, Dana. Her paternal aunt, Carol Winstead Wood, is a Hollywood production designer.
It uses material from the Wikipedia article "Evan Rachel Wood."

redpajama_set_name: RedPajamaCommonCrawl


If the business hours of Butterfass, Pepe & MacCallan in may vary on holidays like Valentine's Day, Washington's Birthday, St. Patrick's Day, Easter, Easter eve and Mother's day. We display standard opening hours and price ranges in our profile site. We recommend to check out bpmi.com for further information. You can also search for Alternatives for bpmi.com on our Review Site Sitebook.org All trademarks are the property of their respective owners. If we should delete this entry, please send us a short E-Mail.


text:
ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology
Ingrid E. Scheffer, Samuel Berkovic, Giuseppe Capovilla, Mary B. Connolly, Jacqueline French, Laura Guilhoto, Edouard Hirsch, Satish Jain, Gary W. Mathern, Solomon L. Moshé, Douglas R. Nordli, Emilio Perucca, Torbjörn Tomson, Samuel Wiebe, Yue Hua Zhang, Sameer M. Zuberi
1144 Scopus citations
The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.
https://doi.org/10.1111/epi.13709
Epilepsy syndromes
10.1111/epi.13709
Fingerprint Dive into the research topics of 'ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology'. Together they form a unique fingerprint.
Terminology Medicine & Life Sciences
Epilepsy Medicine & Life Sciences
Seizures Medicine & Life Sciences
Generalized Epilepsy Medicine & Life Sciences
Partial Epilepsy Medicine & Life Sciences
Epileptic Syndromes Medicine & Life Sciences
Brain Diseases Medicine & Life Sciences
Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., Nordli, D. R., Perucca, E., Tomson, T., Wiebe, S., Zhang, Y. H., & Zuberi, S. M. (2017). ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 58(4), 512-521. https://doi.org/10.1111/epi.13709
ILAE classification of the epilepsies : Position paper of the ILAE Commission for Classification and Terminology. / Scheffer, Ingrid E.; Berkovic, Samuel; Capovilla, Giuseppe; Connolly, Mary B.; French, Jacqueline; Guilhoto, Laura; Hirsch, Edouard; Jain, Satish; Mathern, Gary W.; Moshé, Solomon L.; Nordli, Douglas R.; Perucca, Emilio; Tomson, Torbjörn; Wiebe, Samuel; Zhang, Yue Hua; Zuberi, Sameer M.
In: Epilepsia, Vol. 58, No. 4, 01.04.2017, p. 512-521.
Scheffer, IE, Berkovic, S, Capovilla, G, Connolly, MB, French, J, Guilhoto, L, Hirsch, E, Jain, S, Mathern, GW, Moshé, SL, Nordli, DR, Perucca, E, Tomson, T, Wiebe, S, Zhang, YH & Zuberi, SM 2017, 'ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology', Epilepsia, vol. 58, no. 4, pp. 512-521. https://doi.org/10.1111/epi.13709
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr 1;58(4):512-521. https://doi.org/10.1111/epi.13709
Scheffer, Ingrid E. ; Berkovic, Samuel ; Capovilla, Giuseppe ; Connolly, Mary B. ; French, Jacqueline ; Guilhoto, Laura ; Hirsch, Edouard ; Jain, Satish ; Mathern, Gary W. ; Moshé, Solomon L. ; Nordli, Douglas R. ; Perucca, Emilio ; Tomson, Torbjörn ; Wiebe, Samuel ; Zhang, Yue Hua ; Zuberi, Sameer M. / ILAE classification of the epilepsies : Position paper of the ILAE Commission for Classification and Terminology. In: Epilepsia. 2017 ; Vol. 58, No. 4. pp. 512-521.
@article{0598443e9d6940c5b9ec680cd0e94664,
title = "ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology",
abstract = "The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.",
keywords = "Classification, Epilepsy syndromes, Etiology, Terminology",
author = "Scheffer, {Ingrid E.} and Samuel Berkovic and Giuseppe Capovilla and Connolly, {Mary B.} and Jacqueline French and Laura Guilhoto and Edouard Hirsch and Satish Jain and Mathern, {Gary W.} and Mosh{\'e}, {Solomon L.} and Nordli, {Douglas R.} and Emilio Perucca and Torbj{\"o}rn Tomson and Samuel Wiebe and Zhang, {Yue Hua} and Zuberi, {Sameer M.}",
note = "Funding Information: Ingrid Scheffer received support from and/or has served as a paid consultant for UCB, Eisai, Athena Diagnostics, GlaxoSmithKline, Transgenomics, and Biocodex. She serves on the editorial boards of Neurology and Epileptic Disorders. She has received grants from the National Health and Medical Research Council, Australian Research Council, National Institutes of Health (NIH), Human Research Council, Citizens United for Research in Epilepsy (CURE), the US Department of Defense, and the March of Dimes. Samuel Berkovic discloses payments from UCB Pharma, Novartis Pharmaceuticals, Sanofi-Aventis, and Jansen Cilag for advisory board and educational activities, and a patent for SCN1A testing held by Bionomics Inc licensed to various diagnostic companies. Giuseppe Capovilla serves on the editorial board of the European Journal of Pediatric Neurology. Mary Connolly has received research grants and/or speakers honoraria from UCB, Novartis, Biocodex, Eisai, and Sage Therapeutics. All honoraria are donated to the Epilepsy Research and Development Fund. She has also received research grants from CIHR (Canadian Institute for Health Research) and The Alva Foundation. She is Co-Chair of the Canadian Paediatric Epilepsy Network. Jacqueline French: The Epilepsy Study Consortium pays her university employer for her consultant time related to Acorda, Anavex, Brabant Pharma, Bio-Pharm Solutions, Eisai Medical Research, GlaxoSmithKline, GW Pharma, Impax, Johnson & Johnson, Marinus, Neusentis, Novartis, Roivant, Pfizer, Sage, Sunovion, SK Life Sciences, Supernus Pharmaceuticals, Takeda, UCB, Upsher-Smith, Ultragenyx, Vertex, Zogenix, Zynerba, and the Scientific Advisory Board for Anavex, UCB; grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK Life Sciences, UCB, Upsher-Smith, and Vertex; and grants from National Institute of Neurological Disorders and Stroke, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium. She is on the editorial board of Lancet Neurology, Neurology Today, and Epileptic Disorders, and is an Associate Editor of Epilepsia, for which she receives a fee. Laura Guilhoto: serves on the editorial board of Seizure?European Journal of Epilepsy. Edouard Hirsch has received support from UCB, and/or has served as a paid consultant for UCB, Eisai, and Bial. Satish Jain and Yue-Hua Zhang have no disclosures. Gary Mathern is partially supported by the Davies/Crandall Chair for Epilepsy Research at UCLA and is co-editor in chief for Epilepsia and Epilepsia Open. He is also on the editorial board of Neurology, and the Data Management Committee for NeuroPace, Inc. Solomon L. Mosh? MD is the Charles Frost Chair in Neurosurgery and Neurology and funded by grants from NIH NS43209 and 1U54NS100064-01, CURE Infantile Spasms Initiative, the US Department of Defense (W81XWH-13-1-0180), the Heffer Family and the Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. He serves as Associate Editor of Neurobiology of Disease, and is on the editorial boards of Brain and Development, Pediatric Neurology, and Physiological Research. He receives from Elsevier an annual compensation for his work as Associate Editor of Neurobiology of Disease and royalties from two books he co-edited. He received a consultant's fee from Eisai and UCB. Douglas Nordli is funded from NIH (1-RO1-NS43209) and CURE. He is an Associate Editor for UpToDate. Emilio Perucca has received speaker's or consultancy fees and/or research grants from the following pharmaceutical companies: Eisai, Biopharm Solutions, GW Pharma, Mylan, Sanofi, SK Life Sciences, Sun Pharma, Takeda, and UCB Pharma. Torbj?rn Tomson has received research grants and/or speakers honoraria to his institution from the following pharmaceutical companies: Eisai, GlaxoSmithKline, Novartis, Bial, and UCB. He has also received research grants from CURE, Stockholm County Council, and EU (DG Sante). Samuel Wiebe has received speaker's or consultancy fees and/or research/educational grants from UCB, Electrocore, and Sunovion. Sameer Zuberi has received research support and or speaker? honoraria/consultancy fees from Epilepsy Research UK, Dravet Syndrome UK, UCB Pharma, Yorkhill Children's Charity, GW Pharma, Brabant Pharma, and Zogenix. He is Editor-in-Chief of the European Journal of Paediatric Neurology. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",
doi = "10.1111/epi.13709",
journal = "Epilepsia",
T1 - ILAE classification of the epilepsies
T2 - Position paper of the ILAE Commission for Classification and Terminology
AU - Scheffer, Ingrid E.
AU - Berkovic, Samuel
AU - Capovilla, Giuseppe
AU - Connolly, Mary B.
AU - French, Jacqueline
AU - Guilhoto, Laura
AU - Hirsch, Edouard
AU - Jain, Satish
AU - Mathern, Gary W.
AU - Moshé, Solomon L.
AU - Nordli, Douglas R.
AU - Perucca, Emilio
AU - Tomson, Torbjörn
AU - Wiebe, Samuel
AU - Zhang, Yue Hua
AU - Zuberi, Sameer M.
N1 - Funding Information: Ingrid Scheffer received support from and/or has served as a paid consultant for UCB, Eisai, Athena Diagnostics, GlaxoSmithKline, Transgenomics, and Biocodex. She serves on the editorial boards of Neurology and Epileptic Disorders. She has received grants from the National Health and Medical Research Council, Australian Research Council, National Institutes of Health (NIH), Human Research Council, Citizens United for Research in Epilepsy (CURE), the US Department of Defense, and the March of Dimes. Samuel Berkovic discloses payments from UCB Pharma, Novartis Pharmaceuticals, Sanofi-Aventis, and Jansen Cilag for advisory board and educational activities, and a patent for SCN1A testing held by Bionomics Inc licensed to various diagnostic companies. Giuseppe Capovilla serves on the editorial board of the European Journal of Pediatric Neurology. Mary Connolly has received research grants and/or speakers honoraria from UCB, Novartis, Biocodex, Eisai, and Sage Therapeutics. All honoraria are donated to the Epilepsy Research and Development Fund. She has also received research grants from CIHR (Canadian Institute for Health Research) and The Alva Foundation. She is Co-Chair of the Canadian Paediatric Epilepsy Network. Jacqueline French: The Epilepsy Study Consortium pays her university employer for her consultant time related to Acorda, Anavex, Brabant Pharma, Bio-Pharm Solutions, Eisai Medical Research, GlaxoSmithKline, GW Pharma, Impax, Johnson & Johnson, Marinus, Neusentis, Novartis, Roivant, Pfizer, Sage, Sunovion, SK Life Sciences, Supernus Pharmaceuticals, Takeda, UCB, Upsher-Smith, Ultragenyx, Vertex, Zogenix, Zynerba, and the Scientific Advisory Board for Anavex, UCB; grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK Life Sciences, UCB, Upsher-Smith, and Vertex; and grants from National Institute of Neurological Disorders and Stroke, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium. She is on the editorial board of Lancet Neurology, Neurology Today, and Epileptic Disorders, and is an Associate Editor of Epilepsia, for which she receives a fee. Laura Guilhoto: serves on the editorial board of Seizure?European Journal of Epilepsy. Edouard Hirsch has received support from UCB, and/or has served as a paid consultant for UCB, Eisai, and Bial. Satish Jain and Yue-Hua Zhang have no disclosures. Gary Mathern is partially supported by the Davies/Crandall Chair for Epilepsy Research at UCLA and is co-editor in chief for Epilepsia and Epilepsia Open. He is also on the editorial board of Neurology, and the Data Management Committee for NeuroPace, Inc. Solomon L. Mosh? MD is the Charles Frost Chair in Neurosurgery and Neurology and funded by grants from NIH NS43209 and 1U54NS100064-01, CURE Infantile Spasms Initiative, the US Department of Defense (W81XWH-13-1-0180), the Heffer Family and the Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. He serves as Associate Editor of Neurobiology of Disease, and is on the editorial boards of Brain and Development, Pediatric Neurology, and Physiological Research. He receives from Elsevier an annual compensation for his work as Associate Editor of Neurobiology of Disease and royalties from two books he co-edited. He received a consultant's fee from Eisai and UCB. Douglas Nordli is funded from NIH (1-RO1-NS43209) and CURE. He is an Associate Editor for UpToDate. Emilio Perucca has received speaker's or consultancy fees and/or research grants from the following pharmaceutical companies: Eisai, Biopharm Solutions, GW Pharma, Mylan, Sanofi, SK Life Sciences, Sun Pharma, Takeda, and UCB Pharma. Torbj?rn Tomson has received research grants and/or speakers honoraria to his institution from the following pharmaceutical companies: Eisai, GlaxoSmithKline, Novartis, Bial, and UCB. He has also received research grants from CURE, Stockholm County Council, and EU (DG Sante). Samuel Wiebe has received speaker's or consultancy fees and/or research/educational grants from UCB, Electrocore, and Sunovion. Sameer Zuberi has received research support and or speaker? honoraria/consultancy fees from Epilepsy Research UK, Dravet Syndrome UK, UCB Pharma, Yorkhill Children's Charity, GW Pharma, Brabant Pharma, and Zogenix. He is Editor-in-Chief of the European Journal of Paediatric Neurology. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
N2 - The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.
AB - The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.
KW - Classification
KW - Epilepsy syndromes
KW - Etiology
KW - Terminology
U2 - 10.1111/epi.13709
DO - 10.1111/epi.13709
JO - Epilepsia
JF - Epilepsia


text:
Obtain a Business License»
The Penalty for No Business License
by Michael Wolfe
Businesses collect sales taxes from customers and pay the taxes to their revenue agency.
IT Stock Free/Polka Dot/Getty Images
1 What Happens if You Open a Place of Business Without a Certificate of Occupancy?
2 Can I Operate a Sole Proprietorship Without a DBA in Texas?
3 Revive Expired Patents
4 What Is the Difference Between Vicarious & Employers' Liability?
In the United States, all states and nearly all cities require that businesses operating within their borders receive some kind of license from the government before opening the doors. These licenses are mandatory. In order to ensure that prospective business owners do not neglect to receive these licenses, governments impose penalties--usually financial--for a failure to attain the appropriate license. The exact penalty will vary depending on the type of license and the government.
The purpose of a business license is to alert the government to the existence of the business to make sure that it is properly taxed and that the owners are following the guidelines for people operating a business of that type. To receive a business license, a person must apply to the government that issues it. This the same government that will be responsible for fining individuals who fail to attain the license when required.
According to the U.S. Small Business Administration, failing to comply with the requirements of city and state governments issuing business licenses can result in expensive fines. The exact amount of the fine will depend on several factors, including the nature of the offense. For example, if a business misses a filing deadline for renewal, the penalty will likely be less than if the business has operated for several years without a license.
In some cases, a business that is operating without a license will also have its operation suspended. Many business licenses are issued only to individuals who have had some specialized training in the field and undergone the approval. For example, a bar that does not have a liquor license has not gone through the property review process and will likely be shut down. Similarly, a person cannot practice certain professions without a license, such as the medical field.
In very isolated instances, a person may face criminal charges for failing to attain a business license before practicing his trade. Many professionals are required to receive special certification before selling--or, in some cases, even practicing--their services. For example, a doctor can face criminal charges for practicing medicine without a license, as doing so presents a danger to the people he is caring for.
Small Business Administration: Search for Business License and Permits
City of Talladega: Tax Rates, Penalties
Michael Wolfe has been writing and editing since 2005, with a background including both business and creative writing. He has worked as a reporter for a community newspaper in New York City and a federal policy newsletter in Washington, D.C. Wolfe holds a B.A. in art history and is a resident of Brooklyn, N.Y.
Wolfe, Michael. "The Penalty for No Business License." Small Business - Chron.com, http://smallbusiness.chron.com/penalty-business-license-13706.html. Accessed 16 July 2019.
Wolfe, Michael. (n.d.). The Penalty for No Business License. Small Business - Chron.com. Retrieved from http://smallbusiness.chron.com/penalty-business-license-13706.html
Wolfe, Michael. "The Penalty for No Business License" accessed July 16, 2019. http://smallbusiness.chron.com/penalty-business-license-13706.html
What Can Happen If You Open a Business Without a Business License?
The Definition of Licensee
Costs Associated with Business Licenses
Arkansas Food & Catering Permit Requirements
Where to Find Business Licenses
Hookah Bar License Laws
Start a Private Investigating Company
Difference in Business License & Registering a Business
What Are the Strength & Weakness of a Sole Proprietorship?
Is it Required by Law to Have Commercial Liability Insurance?


text:
Megan Washington | Describing a sensation
by Carol Duncan | Sep 22, 2014 | interview, music, work | 0 comments
Megan Washington says that 'Skyline', one of the tracks on her new album 'There, There' is about 'choosing hope'.
"I think that's a choice we have to make daily. Choosing happiness and choosing positivity is something that you have to make a priority. For me, it's a daily thing."
"That song was inspired a few years when I became very ill and woke up in hospital, figuring out how I felt in that moment and what it meant. Those moments can be extremely formulative? Is that a word? The highest of highs and the lowest of lows is when you galvanise your resolve to overcome things and that was one of mine."
Whilst not new to the music industry it would be surprising if her audience hadn't increased substantially after her appearance on ABC TV's Australian Story and her frank discussion of growing up with a stutter. It was wonderful to watch the flood of support from many thousands of people sent to her via social media after the program aired.
"To be honest with you, I cried a lot after that. I watched the show – because I couldn't not watch it – with some friends and we made a dinner and watched it."
"Afterwards, the overwhelming – you used the word 'flood' – and I think that's a great description of it, all these people … it wasn't so much the goodwill that struck me, it was the resonance, the 'me toos', that I heard and I found really moving. I found it incredible that people could see some of themselves in what I had said."
"You've got to understand, I don't know any other version of life than my life. It isn't like I never had a stutter and then I suddenly got one. This is how existence is. To see that brought so many other people together with each other, not so much with me, there was a real sense of us being on the same side, the same team. It's great."
People like to tell each other who they are.
"I think it's universal. When I meet anybody the first thing they want to do is tell you their story. People like to tell each other who they are. It's not surprising to me when people do this and drop the act, stop acting out their role."
The shortest song on Megan Washington's new album was written in just a few minutes and she says she had the aim of trying to describe a sensation.
"There must be a word for that like 'onomatopoeiac' but that describes the sensation, the sound reflects the sensation. There must a word for it, a German word!"
"I wanted to write a song about falling in love that was less about falling in 'lurve' than literally FALLING in love, falling down the stairs or something. The dizziness or giddyness that comes with that. That was the plan. It is the shortest song I've ever written."
Megan Washington's new album 'There, there' is out now and is our 1233 ABC Newcastle Album of the Week.
You can hear Carol Duncan's full interview with Megan Washington in the audio attached.
If you missed Megan's exceptional TedX talk, the link is here.


text:
Northwell Health deploys chatbot to reduce colonoscopy no-shows
A personalized chatbot is helping dispel patients' concerns about colonoscopy appointments – and also helping lower appointment no-show rates – at Northwell Health.
Deployed at Long Island Jewish Medical Center and Southside Hospital, the technology, Colonoscopy Health Chat is based on Conversa Health's automated conversation platform and is offered via text or email.
Northwell is an investor in Conversa, and uses its health chat technology in a variety of patient outreach use cases. Several new chat programs are planned for other patient populations in the coming year.
This chatbot will be offered to all patients who book appointments for colonoscopies at LIJ Medical Center and Southside Hospital. Researchers will then track its impact on patient satisfaction, cancellations and no-show rates – as well as successful completion of the exam, which requires thorough pre-exam colon cleansing.
The chat technology offers information about why that preparation is needed, and explains how to accomplish it as comfortably and effectively as possible.
THE LARGER TREND
Northwell notes that colon cancer is the second-leading cause of cancer deaths, but many people who make an appointment for colonoscopies either cancel it or fail to show up. It cities studies showing that as many as 40% of these patients from vulnerable or disadvantaged populations don't follow-through on the exam.
The Colonoscopy Health Chat uses artificial intelligence to help address misunderstandings and concerns about the exam – offering important information in a responsive and conversational way. In addition to giving date and location reminders, the chats (in both English and Spanish) can help remind patients about the benefits of the test, and explain and what to expect before, during and after the procedure.
Conversa's Conversational AI platform has been deployed across Northwell – which is also currently at work with Allscripts on a redesigned AI-powered electronic health record – in many other areas, including Transitions of Care Post Discharge, Radiation Oncology (Head, Neck, Breast, Prostate), Bariatric Surgery, Complete Joint Replacement, Emergency Medicine / ED Discharge, Colorectal Surgery, Urology Surgery, Women's Health, Telehealth, Pediatrics and Community Health.
"Colonoscopy is a powerful and potentially life-saving procedure, but many people are intimidated or think it will be much more unpleasant than it really is," said Sabina Zak, Northwell Health's vice president of community health and health services research.
"The colonoscopy health chat platform is a flexible, scalable solution that improves health literacy and gives patients the information they need whenever they need it, so that they feel comfortable and motivated to get screened," Zak explained.
"Health literacy is a strong determinant of wellness among vulnerable populations," she added. "By helping patients understand their treatment and the reasons for it, we think the colonoscopy health chat will enable more patients to get the care they need and deserve."
Twitter: @MikeMiliardHITN
Email the writer: [email protected]
Healthcare IT News is a publication of HIMSS Media.
Tags: Accountable Care, Artificial Intelligence, Mobile, Patient Engagement, Population Health
SECRETS OF AN A-LIST BODY: How to get Penelope Cruz's calf muscles
Worrisome statistics around medical cannabis users operating vehicles: More public education and guidelines are needed to increase marijuana users' understanding of cannabis-related driving impairment
HIV infects one teenaged girl every 3 minutes: UN
Too many people missing out on health benefits of golf, says expert panel
Most People Don't Know This: Not Getting Enough Exercise Ups Your Cancer Risk
Diabetic has her leg amputated after ingrown toenail became gangrenous
Actually, Meghan Markle Isn't Going to Drop Archie From His Carrier
Why those essential oil 'flu bombs' circulating online are so dangerous
Jamie Otis Slams Mom-Shamer Criticizing Her for Not Potty-Training Daughter


Items where Author is " Pampalone Selena"
Greco Rosaria, Demartini Chiara, Zanaboni Anna Maria, Redavide Elisa, Pampalone Selena, Toldi József, Fülöp Ferenc, Blandini Fabio, Nappi Giuseppe, Sandrini Giorgio, Vécsei László, Tassorelli Cristina: Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: targets and anti-migraine mechanisms.
This list was generated on 2019. április 20. 00:11:19 CEST.


While I was surfing the Warrior Forum, today I found this "WP Azon Disclaimer", so here is my review. This is an awesome WordPress plugin to protect your Amazon Associates account.
It costs just $4.95 right now, as the price will be kept lower for a few days. This plugin really saves you from random Amazon bans.
In fact all the websites that are promoting Amazon items without a proper disclaimer with your name are risking really much.
So this plugin does a simple and useful task. As soon as you install it, you can choose if publish the website disclaimer directly on footer or on the sidebar as a movable widget.
Just add your name and surname, and click the websites of the Amazon network you are promoting objects for, and you are done!
I recommend you to put the final Amazon disclaimer on your sidebar, or at least on the footer. So that it's visible to all (Amazon included!).
And as soon as the Big A will change his rules, this plugin will be updated with brand new disclaimers. It's like having a lawyer that works for you, full time!
But all what you pay for this awesome "WP Azon Disclaimer" is $4.95, if you are fast enough.
So keep your Amazon profits secured, and go for it!


text:
Investment no-no's not just for novices
Marketplace Staff Jan 12, 2007
https://www.marketplace.org/2007/01/12/investment-no-nos-not-just-novices/
KAI RYSSDAL: Most of us shop hard for big ticket items like a car. After all, why pay more than you have to? But then we turn around and don't shop smart for a more pricey item. An investment portfolio can cost tens or hundreds of thousands of dollars over your lifetime. But we rarely look for bargains when we shop for things like mutual funds. You can blame it on how most of us, even financial elites, behave around money. Marketplace's Steve Tripoli explains.
STEVE TRIPOLI: Why do so many people buy mutual funds that charge high fees? Three researchers in behavioral economics couldn't figure it out. So they took a bunch of financially savvy graduate students from the University of Pennsylvania's elite Wharton Business School. The students were given a hypothetical $10,000. They also got prospectuses describing four index mutual funds that track the S&P 500. They were told to invest that $10,000 however they liked among those four funds. They could even put it all in one fund. And guess what?
BRIDGETTE MADRIAN: Only a very small fraction of students picked the lowest fee portfolio, which would, of course, be the sensible thing to do in this case.
Sensible because one S&P 500 index fund has pretty much the same investment return as any other. That's why the researchers, including Bridgette Madrian of Harvard, who you just heard, used index funds in the study. But investment returns aren't the only way to measure a fund's gains over time. Fees for these funds ranged from $309 in the first year to $589. That info was included in the students' prospectuses. Yet almost all of them failed to stick all their money in the lowest cost fund. Again, Bridgette Madrian.
MADRIAN: One conclusion is that investors don't know what information is most salient in making an asset allocation decision.
Hmm, the researchers thought. Maybe the prospectuses were too long, or too confusing. So they tried again. But this time, each student got a one-page cheat sheet where all the fees were in large, bold numbers. Results? Over 80 percent still didn't go for the lowest cost fund. Harvard's David Laibson is another of the researchers.
DAVID LAIBSON: If Wharton MBA students don't understand this on something as simple as an index fund, we've got to worry more broadly about the general public's understanding of the financial products that they're buying, particularly when those products get more complex than an index fund.
Laibson and Bridgette Madrian say people just don't understand how important fees are. Annual fees for index mutual funds range from a tenth of a percent of the money invest to about 2 and a half percent. That's the same as buying a box of Cheerios for $50 when you can get it for $2 elsewhere. But Laibson says that's far from the worst of this.
LAIBSON: A tiny difference in the fee compounds over time and can make an enormous difference in terms of your final accumulation for retirement.
If you're paying even an extra 1 percent a year in mutual fund fees, that can knock your final retirement kitty down by 30, 40, even 50 percent. Laibson says one problem is that most mutual fund ads don't talk about fees. They talk about past investment performance. Yet by law, they have to say in the same ad that past performance is no indication of future returns. So they're side-stepping the important stuff and playing to our own bad behavioral instincts.
LAIBSON: It's a very natural intuition that what happened yesterday will happen again today. So, buy and large, though it's hard, you kind of want to put blinders on yourself and not pay too much attention to what the fund did last quarter, last year or even over the last few years.
In a separate experiment, Wharton students got that one wrong too. They chased seemingly hot past returns. But at least we can learn from their mistakes. Here's what to know — fees are very important. So shop for the lowest in the fund class you want and fight your urge to chase past returns. Because if you don't overcome the bad money instincts wired into most of us, there are lots of folks out there who are more than ready to take advantage.
RYSSDAL: Steve, hang on just one second. Don't go anyplace. You mentioned in your piece that a lot of people don't see the importance of mutual fund fees. But I don't know, it's my experience that you can't even see the fees to begin with, that they're so deeply buried in there.
TRIPOLI: Unfortunately, that's true, Kai. You know, the cost of buying and owning mutual funds is not as apparent as most other prices are. In fact, it's horribly unapparent to a lot of consumers and most of the industry, I think, likes it that way.
First of all, they're buried in a prospectus where they're hard to find as well as being hard to interpret. And then there are fees beyond the annual charge. Some funds have so-called loads, which is an upfront percentage you pay whenever you put money in. Loads are a bad idea if you're an investor. And then there are so-called 12b1 fees some firms tack on for advertising. That's another one to avoid. It's tough to add it all up.
RYSSDAL: Well what's the average investor to do? I mean, you know, you and I study this a lot and we can't find them. What can you do besides reading more about them and looking for them?
TRIPOLI: Well, you know, a word first about financial literacy education that a lot of people say is the answer. It's not a short-term solution. That's because, quite frankly we need so much of it in this country right now that it'll take a generation to educate most folks adequately. So financial education alone can't penetrate quickly or broadly enough.
The folks I interviewed for this story say government regulators may be starting to realize that and they're also starting to see that the current state of consumer disclosures may not be adequate. So don't forget, all those prospectuses investors get were an attempt to give consumers what they need to choose mutual funds wisely but the behavioral economists in the story keep proving that most of us still don't choose wisely. So it may be more on the regulatory front.
RYSSDAL: Well, what's that going to be? I mean if they tried with prospectuses. I mean, come one, they go straight into the recycling in my house. What more regulation can there be?
TRIPOLI: You know, one possible model is the food nutrition labels we now see on things we eat. They're short. They give a standard set of information and they're easy to understand. You know they're by no means perfect, but now a lot more folks can tell whether that box of crackers they pick up has more fat or sugar or salt or transfats than they want to eat. So a label like that for mutual funds could tell you more about whether a fund has too many of those empty calories called fees.
RYSSDAL: Empty calories, yeah. You know it's a different retirement and personal finance planning world out there. I mean stakes are way higher now than they were a generation ago. What are the near term solutions that are going to help with a problem that we're not going to, you know, realize the full effects of for another 25 years?
TRIPOLI: Well there's one fact that the behavioral economists find intriguing it's that person who runs your company's 401k retirement plan, the plan administrator. Those people, overall, are more savvy than the rest of us. They also control most of our choices of retirement funds because most of what you invest for retirement is through funds that they choose for your company's plan. So the thought is to get this much smaller group on board with offering only a menu of low-cost funds in company plans. That's a good way to short-circuit our own bad behavioral instincts. It just takes the bad choices away and then we'll all have a little breathing room to get educated about this new world and we won't lose an arm and a leg while we're doing it.
RYSSDAL: We'll talk about it again, I'm sure. Marketplace's Steve Tripoli. Thanks, Steve.
TRIPOLI: Thanks, Kai.
Mutual aid grows in popularity during protests and pandemic
College communities rally together to support students struggling with campus departures
70% of college students graduate with debt. How did we get here?
Younger investors prefer computers to human advisors
You and me? We want to maximize shareholder value, too
How to invest in a better world


text:
Home > News > Trending news > Bayer's regorafenib kicks off brain cancer platform trial
Bayer's regorafenib kicks off brain cancer platform trial
Pharmaphorum | June 20, 2019
Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer. GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international trial testing several therapies for patients with newly diagnosed and recurrent glioblastoma. Using a master protocol, several therapies or combinations of therapies from pharma companies can be tested simultaneously, with potential treatments added or dropped from the phase 2/3 trial over time. The idea is to adopt a more efficient approach to testing new therapies for glioblastoma, and Bayer is starting proceedings by opening enrolment for US patients in an arm evaluating its cancer drug regorafenib. Sponsored by the non-profit charitable organisation the Global Coalition for Adaptive Research (GCAR), by the end of the year GBM AGILE will open in over 40 academic medical centres and community-based institutions across the US. There are plans to expand across Europe, China, Canada, and Australia through 2020. GCAR aims to expand and replicate what is learned using this model for GBM to benefit patients with other rare and deadly diseases. A similar approach has already been used in breast cancer, where the I-SPY trials have used a platform design to test several different breast cancer drugs against the same control group. This represents a more efficient and ethical approach that reduces the number of patients required, and limits exposure to the potentially less effective standard therapy.
Study Finds Vegan Diets Boost Gut Hormone That Helps With Weight Loss
According to UPI, a new study found that a vegan diet can help reduce blood sugar and body weight. Men who ate vegan meals saw a boost in their gastrointestinal hormones, which help manage weight. The beneficial gut hormones also enhance insulin secretion, regulate blood sugar, and keep us feeling full longer. The study's lead author said this research "has important implications for those with type 2 diabetes or weight problems." According to the National Institutes of Health, approximately 30 million people in the U.S. have diabetes.
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
McQuade | January 06, 2022
The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs. "Exploring multiple paths is essential as we work to address the unique needs of individuals living with mental health conditions. We look forward to collaborating with Mindset on these assets and are hopeful that medical psychedelics could be approved to treat mental illness in the future." Robert McQuade, Ph.D., president, McQuade Center for Strategic Research and Development, LLC, and chief strategic officer, Otsuka Pharmaceutical Development & Commercialization, Inc MSRD, which identifies and supports early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders, will financially and operationally support the development of two families of Mindset's novel medical psychedelic compounds through Phase 1a and Phase 1b clinical trials. MSRD has made an upfront cash payment of $5 million USD to Mindset and under the terms of the agreement, MSRD and Mindset may agree to expand the collaboration to continue to develop the compounds as pharmaceutical products. In addition, Mindset has granted MSRD a right of first refusal with respect to any asset sale, exclusive licensing or collaboration opportunities pertaining to the drugs and a right of first negotiation with respect to a merger, acquisition or asset sale related to Mindset, both in exchange for the upfront payment, further collaboration, and funding of the development of Mindset's novel compounds. MSRD also has the ability to potentially receive single-digit percentage royalty payments under certain circumstances when the right of first refusal is not consummated or the agreement is terminated. "It is our great pleasure to collaborate with MSRD, a member company of Otsuka, to further the development of two of our families of novel psychedelic compounds. We look forward to leveraging their extensive experience in drug development and CNS indications to accelerate and de-risk our development pathway as we prepare to launch clinical trials," said James Lanthier, chief executive officer of Mindset. "There is a high unmet need for innovative treatments of mental illness. This collaboration further validates our belief that optimized and patentable next-generation psychedelic compounds will be the future of treatments for mental illness." Mr. Richard Patricio, chairman of Mindset's board, added, "This transformational transaction is a validation of what our team has accomplished over the last several years. We are ecstatic that Otsuka has chosen to collaborate with Mindset in the novel psychedelic drug development space and see this as a pivotal moment in Mindset's maturation. Our team is excited to work closely with MSRD to help meet the unmet needs of millions of people worldwide suffering with a variety of mental disorders. The future is truly exciting." About Mindset Pharma Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds. For further information on Mindset, About the McQuade Center for Strategic Research and Development (MSRD) Established in 2019, by the Otsuka pharmaceutical business in the U.S., the mission of MSRD is to search for, identify, and fund innovative early-stage research and development programs that have the potential to build the future portfolio of Otsuka products. Otsuka is dedicated to investing in innovative and creative products in areas of unmet need and MSRD was created as an extension of this commitment to support and identify early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: "Otsuka–people creating new products for better health worldwide." Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx's Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials
Hemogenyx Pharmaceuticals plc | January 13, 2022
Hemogenyx Pharmaceuticals plc the biopharmaceutical group developing new therapies and treatments for blood diseases, and Selexis SA, a JSR Life Sciences company, have signed a service agreement to develop the cell line for Hemogenyx's CDX bispecific antibody for the treatment of acute myeloid leukemia (AML). Under the agreement, Hemogenyx will leverage Selexis' proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines. The CDX bispecific is made using the Hemogenyx's proprietary humanised monoclonal antibody against a target on the surface of AML cells. CDX was co-developed by Hemogenyx Pharmaceuticals and Eli Lilly and Company ("Lilly"). This cutting-edge application of immune therapy offers a potentially more benign and effective form of treatment that, if successful, could have a significant impact on treatment and survival rates for AML. CDX is planned to be the Company's second therapeutic candidate to enter clinical trials. Following the completion of the co-development phase, Lilly granted the Company an exclusive worldwide license to certain intellectual property developed by Lilly related to the CDX bispecific antibody for all uses, including the treatment of AML and other blood cancers. "We are delighted to partner with Selexis, and access its proprietary protein expression tools and technologies, IP and know-how. The partnership is key to advancing our CDX programme into clinical trials and accelerating the timeline to deliver this innovative therapy to patients in need of a more benign and effective treatment for AML." Dr. Vladislav Sandler, Chief Executive Officer and co-founder of Hemogenyx Pharmaceuticals Mr. Dirk Lange, CEO of Selexis, added, "There's an urgent need for effective treatments for AML, and we at Selexis are pleased to apply our technologies to help Hemogenyx advance the CDX bispecific antibody to the clinic. We've built a reputation for delivering cell lines rapidly and cost-effectively, without compromising safety. This is an exciting milestone for Hemogenyx and we welcome the opportunity to join the company on its journey toward delivering a promising and effective therapy for patients with AML." Selexis' modular SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines, providing seamless integration of the development continuum from discovery to commercialization. About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. About Selexis SA Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 146 drug candidates in preclinical and clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company's technologies shorten development timelines and reduce manufacturing risks.
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Vifor Pharma Group | December 15, 2021
Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion. CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assumes a dividend of CHF 2 expected to be declared at the AGM of 26 April, consistent with past practice. The tender offer represents an implied premium of approximately 61% to the unaffected closing price of Vifor Pharma on 1 December 2021 and a 47% premium to Vifor Pharma's unaffected 1-month VWAP as of 1 December 2021.2 Patinex AG, Vifor Pharma's largest shareholder holding 23.2% has agreed to tender its shares into the offer. The Transaction remains subject to the conditions and further terms including: Minimum acceptance rate of 80% of all Vifor Pharma shares on a fully diluted basis; and further customary offer conditions, including regulatory approvals. The tender is currently expected to commence around 18 January 2022 and the transaction is expected to complete around mid-2022. The Board of Directors of Vifor Pharma considers that the proposed transaction respects the interests of all stakeholders and is unanimously recommending the offer to shareholders. There is committed financing for the deal and a strong commitment to pursue regulatory clearances. "Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies. The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders." Jacques Theurillat, Chairman of the Board of Directors Vifor Pharma Group The transaction will enable Vifor Pharma to leverage CSL's global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant. Centerview Partners UK LLP is acting as exclusive financial advisor to Vifor Pharma on the transaction. IFBC have been retained as Fairness Opinion providers by the Vifor Pharma Board of Directors. About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange About CSL CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
Dermaliq Therapeutics | January 18, 2022
Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and licensed Intellectual Property (IP) related to the field of dermatology to Dermaliq. Skin diseases are the fourth leading cause of non-fatal disease burden worldwide, underscoring the role of dermatology in the growing field of global health. Skin conditions have significant impact on patients' well-being, mental health, and social participation. Although topical and local delivery of active ingredients to diseased skin is the preferred treatment route for the majority of patients, current therapies often lack satisfactory skin penetration and patient compliance. Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The unique and proprietary technology now owned by Dermaliq, called hyliQ™, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of superior, highly effective liquid drug products with exceptional cosmetic properties. The proceeds will be used to conduct three Phase 1/2a clinical dermatology programs with the goal to demonstrate safety and efficacy and to advance this novel skin care drug category to market to improve the lives of millions of patients: DLQ01 is a liquid drug candidate for the topical treatment of female and male androgenetic alopecia, targeting the prostamide E2 (PGE2) receptor in hair bulbs through specific follicular drug delivery. DLQ02 is a novel and liquid topical calcineurin inhibitor drug therapy for plaque psoriasis, particularly in difficult to treat areas. DLQ03 is a broad-spectrum liquid antibiotic drug candidate that targets topical treatment of bacterial skin and soft tissue infections, including the reduction of antibiotic-resistant strains. The Company has demonstrated proof-of-principle for enhanced topical drug delivery using hyliQ™ in nonclinical models for all three applications. "We are excited that 3E Bioventures Capital and Beijing Whale Technology Corporation have committed to support Dermaliq as new investors in the Series A round. Our spin-off from Novaliq and successful raising of significant funds provides us with the opportunity to build a leading specialty pharmaceutical company and expand the application of Novaliq's transformative drug delivery technology into dermatology." Dr. Frank Löscher, Chief Executive Officer of Dermaliq "3E is committed to investing in global leading life sciences and biomedical companies and help them grow with access to globalized resources and capabilities," said Karen Liu, Managing Director 3E Bioventures Capital. "Dermaliq is using a unique, and scientifically sound technology to achieve high efficiency drug delivery across the skin. The technology is already proven in ophthalmology and holds great promise for dermatology. We will be excited to explore additional drug pipelines in China and synergize with Dermaliq on both pre-clinical and clinical development." "Whale Technology values the solid science foundation of Dermaliq's proprietary hyliQ™ technology platform," said Ming Gao, founder and Chief Executive Officer of Whale Technology Co. Ltd. "Dermaliq's founding team demonstrates a great combination of science, clinical experience and commercialization strength. We see great potential of Dermaliq's pipeline in the field of dermatology after Novaliq's proven clinical and commercial success in ophthalmology." "Dermatology is the logical next step into using Novaliq's proprietary technology platform outside eye care," said Dr. Christian Roesky, Chief Executive Officer Novaliq. "The spin-off into an independent company allows Dermaliq to greatly benefit from our experience in ophthalmology while being fully committed to the multiple product development activities in dermatology, and likely to further broaden its pipeline to other skin conditions." To reflect the new shareholder structure, Karen Liu of 3E Bioventures Capital will join Dermaliq's Board of Directors. Dr. Löscher has also transitioned from his role as Chief Technology Officer at Novaliq to lead Dermaliq as its CEO & President. About Dermaliq Dermaliq Therapeutics, Inc. is a private company founded in 2021 through a spin off from Novaliq to reimagine topical dermatology. The Company is incorporated in Wilmington (DE), USA under Delaware law. The company has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. About 3E Bioventures Capital 3E Bioventures Capital is a healthcare venture capital firm, dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency. The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution. About Beijing Whale Technology Corporation Ltd Beijing Whale Technology Corporation Ltd. is a China-based pharmaceutical group committed to the long-term sustainable development in the fields of chemistry, pharmaceuticals and aesthetics. With more than 20 years of history, Whale Tech. has developed two core business units. On one hand, Whale Pharmaceutical Co. Ltd., Whale Chemistry Co. Ltd. and Whale Pharmatech Co. Ltd. are grouped as pharmaceutical and chemistry business unit. On the other hand, Whale Biotech is a research stage biotech company with the focus of developing aesthetics products. About Novaliq Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eyedrop technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies.
More Trending news
Pharma 2020: Marketing the future. Which path will you take?
Reimagining the pharma landscape with design thinking


After hitting a snag in the plans for a Downtown Lafayette location, Hook & Boil owner Mark Alleman cleared the air for his customers.
In an open letter posted to the official Hook and Boil Facebook page, Alleman acknowledged the roadblocks he faced during his effort to open a location in Downtown Lafayette. Alleman's efforts are related to a story we reported on surrounding the seizure and sale of the old Filling Station location, which had many wondering what the fate of the original Hook and Boil location would be.
Alleman clears all of it up in his Facebook post telling customers that he and his staff look forward to many "years to come."
Best of luck to Alleman and his crew. Business isn't ever flawless and no rewards are ever realized without risks, so we hope to see him continue to serve up the delicious crawfish that we've come to know and love.
As far as what will occupy the Filling Station location, no one knows. But we can always bet that someone will inevitably mention PF Changs or Dave & Busters.


Set in extensive grounds, Villa Lourdas Ithaki is a 3 bedroom villa located just 15 minutes' walk from Lourdas Beach, tavernas and bars. With a picturesque mountain backdrop, the villa has a large private swimming pool surrounded by a spacious lawn garden - a unique feature for a Greek house. You'll also have wonderful sea views from the first floor. Pool heating, WiFi and air conditioning/heating in all the bedrooms and lounge are included.
Close to Lourdas Beach, great views, a large pool and fantastic garden - a great all-round choice!
The large private swimming pool offers spectacular mountain views and is surrounded by a terrace with sunbeds for relaxing or topping up your tan. There villa has extensive, well-maintained gardens, with mature trees offering privacy and shade. The spacious lawn offers plenty of room for the children to run around. There is a table and chairs for outdoor dining, and a brick BBQ for cooking up some delicious meals.
The villa is set in a complex of 4 villas, which is accessed via a main gate from the road. There is private off-road parking which leads to the villa gardens and front door.
The living and dining area are open plan in style, creating a sociable space. Patio doors keep the room bright and airy and give access out to the villa gardens and pool. The room is pleasantly furnished with comfortable seating, flat screen TV and dining table with chairs. Adjacent is a spacious kitchen furnished with wooden cabinets and well equipped for your holiday meals. Patio doors open out to the villa gardens.
On the ground floor is a twin bedroom with en suite shower room and patio doors opening out to the villa gardens. Upstairs is a second twin bedroom with en suite bathroom and private balcony with spectacular mountain views. Completing the sleeping arrangements is a large double bedroom, with feature wooden beamed ceilings and its own en suite bathroom. This bedroom has access to 2 private balconies, both offering great sea views and a fabulous place to relax with a sundowner.
Villa Ithaki is a detached villa set in a small group of 4 on a residential road above Lourdas Bay. The beautiful sand and shingle beach, plus a selection of restaurants, bars and mini markets are just 15 minutes' walk downhill from the villa. Our villas Lourdas Kefalonia, Lourdas Kerkyra and Lourdas Lefkas are all located in the same residential road.
The nearest mini market is just 625 yards from your villa, great for stocking up on your holiday essentials. There are a number of little shops in Lourdas, but for a greater selection head to Argostoli, the island's capital just 30 minutes' drive away. Here you will find some good clothes shops as well as a local market.
Lourdas has a laid-back atmosphere, with a number of local tavernas serving traditional Greek cuisine as well as some fresh seafood.
Lourdas Beach is the longest stretch on the south coast of Kefalonia, and often referred to as one of the most beautiful beaches on the island. The long sand and shingle beach has sunbeds and parasols for hire, as well as some local tavernas nearby serving lunch and drinks.
For a day of family fun, hire a boat from the beach and explore the beautiful coastline. There are lots of small coves and bays just waiting to be discovered, a perfect spot for a picnic.
The island's capital, Argostoli, is a modern harbour town and well worth a visit for the shopping alone! Alternatively, the Old Village of Skala is just 30 minutes' drive away, where you can explore the old Roman villa with stunning mosaics and enjoy a long lunch with a glass of wine.
There are a few good walking routes from Lourdas, where you can explore the beautiful countryside and admire the stunning scenery.
Villa Lourdas Ithaki is not available to book for season as it is sold out. Take a look here at the Kefalonia villas that are currently on sale.
Villa Ithaki provided us with a relaxing holiday. It offered us total privacy and seclusion in beautiful grounds while only a short walk to the sea and tavernas. Thank you Villa Plus! We have booked another villa with you for 2015 already.


text:
Q: Setting up CodeIgniter to show up on http://localhost/ci/ I downloaded and set-up CodeIgniter and Apache. I have started my Apache server, and in my config.php file in CodeIgniter, I set the base URL to:
$config['base_url'] = "http://localhost/ci/";

However, when I go navigate to that URL (http://localhost/ci/ or http://localhost/ci/index.php), I get a standard 404 Object not found error.
Any idea what else I am missing? When I navigate to localhost, I see the WAMP home page. Not sure if there is anything else I need to set up.
Thanks!

A: You have to set apache alias.
For WAMP (i see this post is tagged as wamp) left click on wamp icon -> Apache -> Alias directories -> Add an alias.
Step-by-step screenshots here.

redpajama_set_name: RedPajamaStackExchange


Accelerated Reader is a computer programme that helps our school to manage and monitor children's independent reading. Children using AR choose their own book from a range of thousands of published titles. AR helps children to choose books at an appropriate readability level that are challenging without being frustrating so that your child can experience success.
Please click on the icons below to access the Accelerated Reader – Home Connect pages.


Nissan Insurance provides quality insurance to protect your vehicle, so you're covered if you have an accident or your vehicle is stolen.
But what if your vehicle is financed and something happens to you? There's your loan and your credit rating to consider, that's why we offer Loan Protection insurance.
We at Nissan Insurance are proud to offer a range of insurance products designed with our customers in mind.
Nissan Prestige Motor Insurance provides comprehensive cover for your vehicle. It offers you benefits you may not find with other covers, including three years new-for-old replacement*, genuine parts** and the choice of your own repairer. You'll find it available only through authorised Nissan dealerships and ready to purchase when you buy your car.
For further information or assistance call Nissan Insurance on 1300 654 975.
*If your vehicle was purchased new or as a demonstrator model by you, and becomes a total loss within three years of the starting date of the original registration, we will replace your vehicle with a new vehicle of the same make, model and series if such a vehicle is available in Australia.
** (Only if the part is locally available at the time of repair .
##Agreed value is not available to all vehicles. You will be advised if agreed value cover is available and if the value required is sufficient for the selected vehicle.
Nissan Prestige Motor Insurance is provided by Allianz Australia Insurance Limited (Allianz) ABN 15 000 122 850, AFS License No. 234708.
Any advice here does not take into account your objectives, financial situation or needs. Terms, conditions, limits and exclusions apply. Before making a decision please consider the relevant Product Disclosure Statement (PDS)/Policy Wording, Supplementary PDS (where applicable) & PDS update (privacy notice) which are available on this website. If you purchase this insurance we receive a commission from Allianz.
How Does it Work With Your Other Insurance?
In the event of the accident, Nissan New Vehicle Extended Warranty Insurance will not cover the costs of repairs to your vehicle. To get cover in an accident, you'll need to take out Nissan Prestige Motor Vehicle Insurance separately.
Nissan New Vehicle Extended Warranty covers the cost of repair or replacement in the event of mechanical failure and the costs that go with it.
If your vehicle suffers a mechanical failure please return your vehicle to us as your selling dealer. If not convenient you can also take your vehicle to an alternative Allianz authorised repairer. They will lodge the claim on your behalf and ensure your vehicle is back on the road as quickly as possible.
*Premiums payable by instalments may be subject to minor adjustments (upwards or downwards) due to rounding and financial institution transaction fees may apply. Please note that if you choose to pay by monthly instalments the total sum of all instalments may be greater than the lump sum policy premium payable if the monthly instalment payment option is not taken.
Nissan Extended Warranty Insurance is provided by Allianz Australia Insurance Limited (Allianz) ABN 15 000 122 850, AFS Licence No. 234708.
Any advice here does not take into account your objectives, financial situation or needs. Terms, conditions, limits and exclusions apply. Before making a decision please consider the relevant Policy Document or Supplementary Product Document (where applicable) which are available on this website. If you purchase this insurance we receive a commission from Allianz.
If you've financed your car, Nissan Loan Protection Insurance is designed to help cover your loan repayments if something happens to you. It covers your minimum monthly repayments in the event of accident, sickness, death, disability or involuntary unemployment, up to the policy limits.
With Nissan Loan Protection Insurance, you receive peace of mind knowing that your minimum monthly loan repayments will be made (up to policy limits) in the event of disability, involuntary unemployment or death. To cover yourself and your car while you're driving on the road, you may want to consider Nissan Prestige Motor Vehicle Insurance.
You can make an Nissan Loan Protection Insurance claim by contacting a claim specialists on 1300 139 664. Claims specialists offer a wealth of experience and are there to help you with your claim during difficult times.
*Terminal illness and death cover is only available to customers over 25 years of age.


text:
Depleted squad comes up trumps
Soccer, SO Hotels Women's National League: DLR Waves 0 Wexford Youths 3
McKenna Davidson on the move in the win away to DLR Waves on Saturday
Dean Goodison in Jackson Park
It's going to take a monumental effort in the coming months, but if Wexford Youths do eventually end up as SÓ Hotels Women's National League champions again, this victory will probably be the most important of the season.
https://www.wexfordpeople.ie/sport/soccer/depleted-squad-comes-up-trumps-38130990.html
https://www.wexfordpeople.ie/sport/soccer/de3e4/38130989.ece/AUTOCROP/h342/2019-05-21_wex_50497424_I2.JPG
Coming off a draw with pretenders Shelbourne, Tom Elmes' side were missing multiple starters due to captain Kylie Murphy's wedding celebrations. Wexford had looked to have the game switched to Wednesday evening, and DLR Waves agreed, but the league didn't.
It meant that just four of this eleven were in the starting line-up seven days earlier, and the same number had started over half of Youths' league games this season. Three were on the field at the beginning of a league game for the first time in 2019.
Had this inexperienced Wexford slipped up in Jackson Park on Saturday, the destination of the title was already out of their own hands.
This was just the eighth league game of the season but it can get late early when you are leaking points in a title race.
So Wexford needed something special and this side produced it. They had to get eleven performances, not eight, not nine, as everyone had to stand up and be counted. Every one of these players took their chance to shine.
Not only did they play with guts, they also played some excellent football. There was a balance in the side, a laid-back freedom in their play. There was also massive enjoyment in what they were doing; these players were in it together and it showed.
Look at the back line, where Doireann Fahey is now the only Wexford player who has started all eight league games but the other three came into this contest with just two league starts between them. They both belonged to Becky Cassin, who never lets her side down when given a chance.
Clíodhna Ní Shé was solid on the right of the defence but the jaw-dropping performer again was Ciara Delaney. The Kilkenny native has had to bide her time more than most, but while others come and restlessly disappear, she stays around and keeps working hard.
Just like when she was called on in the same fixture at the end of last season, Delaney was outstanding. It's getting to the stage where one has to wonder if she's actually one of the best four defenders Wexford have at their disposal.
There might be a comfort in having Delaney on the bench but she knocks on the door every time she is given a chance.
Of course, the level of opponent is not as high as it might be, but at this stage she looks primed for the step up.
Ahead of her, Blessing Kingsley made her first senior league start and was mightily impressive high on the right in the first-half, left in the second.
Aoife Slattery, Lauren Kelly and McKenna Davidson all had their best games of the season in the middle, with the Hawaiian providing a timely reminder that she's a more natural talent in central positions than on the wing.
The first quarter was almost completely uneventful except for one vital moment. Lauren Kelly whipped in a low ball from the right that skidded off the slick surface and was fumbled by Erica Turner, and Katrina Parrock was on her in a flash and the Wexford winger tapped into the empty net.
As the game settled into a pattern, it was the visitors who did most of the pressing. On the other hand, DLR Waves struggled to get a foothold anywhere, and they resorted to long balls into the channels but there was no joy there either.
The impressive Vanessa Ogbonna tested Turner from distance in the 23rd minute, while Kingsley did the same three minutes later.
Those two were involved again 16 minutes before the break, but Ogbonna's searching pass was just cut out by the Waves defence.
Parrock probably should have worked the 'keeper when she met Kelly's corner unmarked, but her header from eight yards out whizzed over the bar.
A low Ogbonna shot almost caught Turner out at her near post in the 42nd minute, but she just about kept it out.
A few half-time tweaks did Wexford no harm, as within a minute Ogbonna broke away on the left and chipped just over the bar.
A minute later her side won a corner, Fahey swung it in low, and Nadine Clare slice-volleyed it into her own net from eight yards out.
Davidson saw her shot easily held by Turner in the 50th minute, but the 'keeper's grip wasn't as solid two minutes later when Delaney's 50-yard strike spun up off the surface, slipped through her fingers, and into the back of the net for 3-0.
That was pretty much game over at that stage. DLR Waves had their first shot, a Rachel Doyle strike that flew well wide, in the 57th minute.
Kerri Letmon added some oomph on the left when she came off the bench, and her shot was held by Maeve Williams 14 minutes from time.
Ogbonna broke away on the left again in the 78th minute, cut in and forced Turner to save with her feet.
The biggest smile of the afternoon came from back-up goalkeeper Sophie Lenehan when she was introduced as a striker in the 83rd minute.
It was her first appearance since the defeat to Peamount but, to her credit, she has been a constant on the Wexford bench. Youths will need her again at some stage, of that there is little doubt, so it's encouraging to see her getting her head down and plugging away, trying to improve.
She almost got her head to a Kelly corner a couple of minutes after coming on and had a few nice touches, but there was no fairytale goal forthcoming.
Kelly was the last to test Turner with a weak enough free-kick, but the Waves stopper held on to this one as Youths went home happy with their lot.
Wexford jump right back into action on Saturday evening, starting a run of four home games in five weekends leading into the mid-season break.
Cork come to Ferrycarrig Park this week (6.30 p.m. kick-off) before Youths host Limerick in the League Cup semi-final seven days later.
Wexford Youths: Maeve Williams; Clíodhna Ní Shé, Ciara Delaney, Becky Cassin, Doireann Fahey; Aoife Slattery; Katrina Parrock (capt.), Lauren Kelly, McKenna Davidson, Blessing Kingsley; Vanessa Ogbonna. Sub. - Sophie Lenehan for Ogbonna (83).
DLR Waves: Erica Turner (capt.); Jenny O'Keeffe, Róisín McGovern, Bobbi Downer, Katie Burdis; Keelin McEntee, Nadine Clare, Ciara Maher, Sinéad Gaynor, Rachel Doyle; Leanne Payne. Subs. - Kerri Letmon for O'Keeffe (72), Niamh Murphy for Doyle (72), Ashling Spillane for Clare (78), also Michaela Fox-Walsh, Sophie O'Donoghue, Aimee Maher, Ally O'Keeffe.
Referee: David Gallagher (Dublin).
Gorey secure deserved win over holders Moyne
Brian Carty Gorey Rangers announced that they are here to stay in the title race when they secured a deserved 2-1 victory over reigning champions Moyne Rangers in Sunday's T.J. Murphy's Sports Bar Premier Division tie in Ramstown.
Rovers on top of the tree for Christmas
Premier Division - Shamrock Rovers maintained their three-point advantage at the top of the Premier Division going into the Christmas break after seeing off Forth Celtic 4-1 on Sunday.
High fives for North End
Dave Devereux in Hollygrove A superb first-half hat-trick from Adam Beary set North End on their way to a comfortable victory in their Premier Division clash in Hollygrove on Sunday.
Gorey secure deserved win over holders Moyne Soccer
A major conference has... Business


UCSUR's Survey Research Program (SRP) has developed and actively maintains a local IRB-approved (PRO11060616) research registry currently containing approximately 7,000 regional residents with detailed socio-demographic and contact information who are willing to take part in research studies. Participants are continually recruited from local population-based telephone surveys conducted by UCSUR. This demographically diverse registry can be used in collaboration with SRP to cost-effectively recruit local participants for externally funded research projects, including repeated panel surveys.
We recently added a series of enrollment questions that determine whether the participant is an unpaid family caregiver. Many people need different kinds of help as they get older, or when they have a serious or long-term illness or disability. Most often the people who provide this help or care are family members, partners, or good friends. They are called family caregivers, using the term "family" broadly. Since this is becoming more common among families, we have added a "caregiver" indicator to allow researchers to access these individuals for caregiver research. Caregivers have also provided all of the registry demographics and geographic data described below. We also collect the age of the care recipient, to allow for studies of specific caregiving sub-populations. Thus far, we have enrolled approximately 1000 local caregiverswilling to be contacted for research studies.


This course focuses on equipping monitoring and evaluation skills to all who undertake it. Monitoring and evaluation skills are on demand in the current competitive business market. Thus, on completion of this course the participant shall acquire skills in monitoring and evaluation that will gain them a competitive advantage in the business market.
Gain familiarity into measures such as credibility, reliability, validity, and precision.
The course targets researchers, NGOs project management officials, ministries in governments, financial institutions, and national statistics officers and volunteers who want to acquire monitoring and evaluation skills.